Chip giant Intel Corporation INTC has joined forces with Israeli pharmaceutical company Teva Pharmaceutical Industries Limited TEVA to develop mechanisms that will better comprehend and examine the progress of still incurable Huntington's disease.
As part of this collaboration, Intel’s Trusted Analytics Platform (TAP) will be used to develop a cloud-based solution for assessing data stored in wearable devices worn by patients under study. The software platform, TAP offers advanced analytics and machine learning solutions.
INTEL CORP PRICE
Some Technical Details
The endeavor will form a part of Teva’s ongoing Huntington's disease drug research program. The new technology solution will be used in a sub-study within a current Phase II study.
Patients will have to use a smartphone and a sensor-fitted smartwatch. The sensor will measure body functioning and movement on a continuous basis and feed data wirelessly to a cloud-based platform. The platform will then execute a real-time conversion of data into scores that will be helpful in analyzing motor symptom severity.
The program will fully leverage on TAP’s algorithm development and movement detection technology.
President of Teva Global R&D and its chief scientific officer Michael Hayden stated, ”Current measurement of symptoms is largely based on observation when the patient sees the doctor. This technology now provides us with an opportunity to have continuous monitoring. This unique technology could complement future trials in HD.”
Other Tech Players Taking to the Field
Intel is not the only company testing waters in the medical technology space. Earlier this month Verily, the life sciences division of Alphabet Inc. GOOGL entered into a joint venture with Sanofi aiming to improve diabetes care.
Verily is also working with Novartis on the development of glucose sensor fitted contact lens and with GlaxoSmithKline on bioelectronics to fight diseases. Alphabet has also partnered with Biogen to study the progression of multiple sclerosis.
Last year, Teva partnered International Business Machines Corporation’s IBM Watson Health Cloud.
Endeavors such as these will undoubtedly aid in the creation of value-based health care systems. They also underscore the fact that technology companies are increasingly trying to have a finger in every pie.
Currently, Intel has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Interested in IPOs? Check out the special edition of Zacks Friday Finish Line below, where Editor Maddy Johnson and Content Writer Ryan McQueeney interview Kathleen Smith of Renaissance Capital about the IPO market in 2016 (see part two here).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research